Hangzhou, China And Shaoxing, China, Nov. 8, 2021 /Prnewswire/ -- Ascletis Pharma Inc. (Hkex: 1672) Announces Today That The Interim Results Of 44 Chronic Hepatitis B (Chb) Patients From A Phase Iib Trial Of Asc22 (Envafolimab), A Subcutaneously Administered Pd-L1 Antibody (Clinicaltrials.Gov Identifier: Nct04465890), Demonstrated Sustained Hbsag Loss In Chb Patients With Baseline Hbsag ? 500 Iu/Ml. The Result Abstract Has Been Selected For Oral Presentation In Late Breaking Session At The Liver Meeting
